Prospecto: information for the user
Oxitocina Kabi 10 UI/ml injectable solution and for perfusion EFG
oxitocina
Read this prospect carefully before starting to use this medicine, because it contains important information for you.
1.What is Oxitocina Kabi and for what it is used
2.What you need to know before starting to use Oxitocina Kabi
3.How to use Oxitocina Kabi
4.Possible adverse effects
5.Storage of Oxitocina Kabi
6.Contents of the package and additional information
Each vial of Oxitocina Kabi contains 16.7 micrograms of oxytocin (equivalent to 10 IU). Oxytocin is a hormone that acts by contracting the smooth muscle of the uterus.
Oxitocina Kabi is used:
Oxitocina Kabi should not be used for prolonged periods if:
If you are in any of these situations or have doubts, consult with your doctor before using Oxitocina Kabi.
Warnings and precautions
Oxitocina Kabi should only be administered by healthcare professionals in a hospital setting.
Consult with your doctor or nurse before starting to use Oxitocina Kabi if:
When administering Oxitocina Kabi to initiate or help contractions during labor, the infusion rate should be adjusted to maintain a contraction pattern similar to a normal and adjusted labor, and tailored to the individual's response. High doses may cause continuous and very strong contractions, and possibly uterine rupture, with serious complications for you and your baby.
Oxitocina Kabi should not be administered as a rapid injection into a vein, as this may cause a decrease in blood pressure, a sudden and brief sensation of heat (often throughout the body), and an increase in heart rate.
Oxitocina Kabi may, in rare cases, cause disseminated intravascular coagulation, which may cause symptoms such as abnormal blood clotting, bleeding, and anemia.
High doses of Oxitocina Kabi may cause amniotic fluid to pass from your uterus into your bloodstream. This is known as amniotic fluid embolism.
Administering high doses over a long period of time while drinking or receiving large volumes of fluid may cause your stomach to feel very full, cause difficulty breathing, and lower your blood sodium levels.
Do not administer simultaneously with a nasal spray containing oxytocin.
If you are in any of the above situations or are unsure, speak with your doctor or nurse before using Oxitocina Kabi.
Allergy to latex
The active ingredient in Oxitocina Kabi may cause a severe allergic reaction (anaphylactic reaction) in patients allergic to latex. Inform your doctor if you are allergic to latex.
Children and adolescents
Oxitocina Kabi is not intended for use in children or adolescents.
Use of Oxitocina Kabi with other medications
Inform your doctor that you are using, have used recently, or may need to use any other medication.
The following medications may interact with Oxitocina Kabi:
Use of Oxitocina Kabi with food and drinks
You may be advised to minimize the amount of liquids you ingest.
Pregnancy, breastfeeding, and fertility
Oxitocina Kabi may induce labor - it should only be used during pregnancy under medical supervision.
Oxitocina Kabi may be found in small amounts in breast milk, but it is not expected to have any adverse effects, as it is rapidly inactivated by your baby's digestive system.
Oxitocina Kabi will not affect your newborn baby during breastfeeding.
Driving and operating machinery
Oxitocina Kabi may induce labor, so you should exercise caution when driving or operating machinery.
Your doctor will decide when and how to treat you with Oxitocina Kabi. If you think the effect of Oxitocina Kabi is too strong or too weak, inform your doctor. While you are receiving Oxitocina Kabi, both you and your baby will be closely monitored.
Oxitocina Kabi is usually diluted before use and administered as an intravenous infusion (drip) in one of your veins. To prepare the intravenous infusion, your doctor may use half of a dose of Oxitocina Kabi 10 UI/ml injectable solution for infusion.
In certain circumstances, 1 ml of undiluted Oxitocina Kabi 5-10 UI may be injected into a muscle.
The usual dose is different in the following circumstances:
To initiate or help contractions during labor
Oxitocina Kabi will be administered as an intravenous infusion by drip in a vein or, preferably, through a variable speed infusion pump. In the case of infusion by drip, it is recommended to add 5 UI of Oxitocina Kabi to 500 ml of a physiological electrolyte solution (such as sodium chloride 0.9%). For patients in whom the infusion of sodium chloride should be avoided, a 5% dextrose solution may be used as a diluent.
The infusion rate will start at 2-8 drops per minute (1-4 milliunits per minute). This may be increased gradually to a maximum rate of 40 drops per minute (20 milliunits per minute). The infusion may often be reduced once contractions reach an adequate level (over 3-4 contractions every 10 minutes).
If your contractions do not reach an adequate level after 0.5 ml of Oxitocina Kabi 10 UI/ml, the attempt to initiate labor should be stopped and repeated the next day.
Cesarean delivery
The dose is 0.5 ml of Oxitocina Kabi 10 UI/ml administered as an intravenous infusion by drip (5 UI diluted in physiological sodium chloride solution) or, preferably, through a variable speed infusion pump for 5 minutes in a vein after delivery of your baby.
Prevention of postpartum hemorrhage
The usual dose is 5 UI by intravenous infusion (5 UI diluted in a physiological saline solution) or 5 to 10 UI by intramuscular injection after expulsion of the placenta.
Treatment of postpartum hemorrhage
The usual dose is 5 UI of Oxitocina Kabi by intravenous infusion (5 UI diluted in a physiological saline solution) or 5 to 10 UI by intramuscular injection. In some cases, this may be followed by an intravenous infusion by drip of a solution containing 5-20 UI of oxytocin in 500 ml of a physiological saline solution.
Spontaneous abortion
Given the lesser expression of receptors, it is recommended to use oxytocin from week 14 of pregnancy. The dose is 5 UI or 0.5 ml of Oxitocina Kabi 10 UI/ml administered as an intravenous infusion by drip (5 UI diluted in physiological sodium chloride solution) or, preferably, through a variable speed infusion pump for 5 minutes in a vein, if necessary followed by an intravenous infusion at a rate of 20 to 40 milliunits/minute.
Patients with liver or renal insufficiency
There is no information on use in patients with renal or hepatic insufficiency.
Older adults
There are no indications for the use of Oxitocina Kabi in older adults.
If you use more Oxitocina Kabi than you should
Since this medication will be administered to you in the hospital, it is very unlikely that you will receive an overdose. If an accidental overdose occurs, inform the hospital and emergency services or a doctor immediately. Show your doctor the medication or the empty container.
An overdose of Oxitocina Kabi could cause:
If you forget to use Oxitocina Kabi
Since this medication is administered by a doctor, it is unlikely that you will forget a dose. If you have any concerns, speak with your doctor.
If you have any doubts about the use of this medication, consult with your doctor or nurse.
If you interrupt treatment with Oxitocina Kabi
The infusion of Oxitocina Kabi may be withdrawn gradually once labor progresses.
There is no information about adverse effects.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Stop taking Oxitocina Kabi and contact a doctor or go to the nearest emergency serviceimmediatelyif you experience any of the following symptoms:
Other side effects that may occur:
Frequent(may affect more than 1 in 100 patients):
Occasional(may affect more than 1 in 1,000 patients):
Rare(may affect more than 1 in 10,000 patients):
Unknown frequency
Effects on the baby:
Excessive contractions may cause low sodium levels, lack of oxygen, asphyxia, and death.
Reporting of adverse effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Store in refrigerator (between 2°C and 8°C). Do not freeze.
Keep out of sight and reach of children.
Do not use this medicine after the expiration date that appears on the packaging and on the ampoule label after CAD. The expiration date is the last day of the month indicated.
After the first opening: the medicine must be used immediately.
After dilution for infusion: from a microbiological point of view, unless the opening/reconstitution/dilution method excludes the risk of microbial contamination, the medicine must be used immediately. If not used immediately, storage times and previous conditions for use are the responsibility of the user and are normally not greater than 24 hours at a temperature of 2 to 8 °C.
Do not use any container that is damaged or shows signs of manipulation.
Do not use this medicine if you observe that the ampoule content is cloudy or has particles or lumps.
Medicines should not be disposed of through drains or in the trash. If in doubt, ask your pharmacist how to dispose of the containers and medicines that you no longer need. In this way, you will help protect the environment.
Composition ofOxitocina Kabi
1 ml of solution contains 16.7 micrograms of oxytocin (10 UI)
Appearance of the product and contents of the container
Clear, colorless, and particle-free liquid.
The pH of the solution is 3.5-4.5.
1 ml glass type I (borosilicate) ampoules with break ring or O.P.C. opening system. Container sizes of 5, 10, or 100 ampoules.
Only some container sizes may be marketed.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization
Fresenius Kabi España, S.A.U.
Marina 16-18, 08005 – Barcelona
Spain
Responsible for manufacturing
AS Grindeks
Krustpils iela 53,
Riga, LV-1057, Latvia
This medicine is authorized in the member states of the European Economic Area with the following names:
SwedenOxytocin Grindeks 16.7 mikrogram/ml injection-/infusion fluid, solution
AustriaOxytocin Grindeks16,7 Mikrogramm/ml Injections-/Infusions solution
BelgiumOxytocin Grindeks10 IU/ml injectable/pour perfusion solution
Czech RepublicOfost 10 IU/ml injekční/infuzní solution
FranceOxytocine Grindeks 10 U.I./1 mL, injectable/pour perfusion solution
GermanyOFOST 10 IU/ml solution for injection/infusion
HungaryOxytocin Grindeks 10 NE/ml oldatos injection/infusion
IrelandOfost 10 IU/mlconcentrate for solution for infusion or solution for intramuscular injection
ItalyOssitocina Pharmexon 10 IU/ml injectable/per infusion solution
LatviaOfost 10 IU/ml šķidruma injekcijam/infuzijam
LithuaniaOfost 10 TV/ml injekcinis ar infuzinistirpalas
PolandOxytocin Grindeks16,7mikrogramów/ml solution for injection/infusion
PortugalOxitocina Kabi10UI/ml injectable or for perfusion solution
RomaniaOfost 16.7 micrograme/ml injectable/perfusion solution
SlovakiaOfost 10 IU/ml injekčný a infúzny solution(injekcia/infúzia)
SloveniaOfost 10 i.e./ml solution for injection/infusion
SpainOxitocina Kabi 10 UI/ml solutioninjectable and for perfusion EFG
This leaflet has been revised in October 2021.
The detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.